Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Finished Goods (2021 - 2025)

Universe Pharmaceuticals' Finished Goods history spans 5 years, with the latest figure at $1.6 billion for Q3 2025.

  • For Q3 2025, Finished Goods rose 40.91% year-over-year to $1.6 billion; the TTM value through Sep 2025 reached $1.6 billion, up 40.91%, while the annual FY2025 figure was $1.6 billion, 40.91% up from the prior year.
  • Finished Goods for Q3 2025 was $1.6 billion at Universe Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $1.6 billion in Q3 2025 and bottomed at $1.3 million in Q3 2022.
  • The 5-year median for Finished Goods is $2.8 million (2023), against an average of $551.2 million.
  • The largest annual shift saw Finished Goods tumbled 32.14% in 2022 before it skyrocketed 40997.28% in 2024.
  • A 5-year view of Finished Goods shows it stood at $2.0 million in 2021, then tumbled by 32.14% to $1.3 million in 2022, then skyrocketed by 107.64% to $2.8 million in 2023, then surged by 40997.28% to $1.1 billion in 2024, then surged by 40.91% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Finished Goods are $1.6 billion (Q3 2025), $1.1 billion (Q3 2024), and $2.8 million (Q3 2023).